Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
- Authors: Grechukhina K.S1,2, Vorontsova K.A1, Kuko T.M1, Prosvirnov A.A1, Ganshina I.P3, Lubennikova E.V3, Kolyadina I.V4,5, Zhukova L.G1
-
Affiliations:
- A.S. Loginov Moscow Clinical Research Center
- Lomonosov Moscow State University
- N.N. Blokhin National Medical Research Center of Oncology
- National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Acad. V.I. Kulakov
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 28, No 7 (2021)
- Pages: 15-27
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313174
- DOI: https://doi.org/10.18565/pharmateca.2021.7.15-27
- ID: 313174
Cite item
Abstract
Full Text
About the authors
K. S Grechukhina
A.S. Loginov Moscow Clinical Research Center; Lomonosov Moscow State University
Email: dr.grechukhina@gmail.com
Moscow, Russia
K. A Vorontsova
A.S. Loginov Moscow Clinical Research CenterMoscow, Russia
T. M Kuko
A.S. Loginov Moscow Clinical Research CenterMoscow, Russia
A. A Prosvirnov
A.S. Loginov Moscow Clinical Research CenterMoscow, Russia
I. P Ganshina
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
E. V Lubennikova
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
I. V Kolyadina
National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Acad. V.I. Kulakov; Russian Medical Academy of Continuous Professional EducationMoscow, Russia
L. G Zhukova
A.S. Loginov Moscow Clinical Research CenterMoscow, Russia
References
- Fry D.W., Bedford D.C., Harvey P.H., et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J boil Chem. 2001;276(20):16617- 23. doi: 10.1074/jbc.M008867200
- Lallemand L., Duhoux F.P. CDK4/6 inhibitors in the treatment of advanced breast cancer. Belg J Med Oncol. 2017;11(5):234-41
- Prall O.W., Sarcevic B., Musgrove E.A., et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclinE-Cdk2.JBoilChem.1997;272(16):10882- 94. doi: 10.1074/jbc.272.16.10882
- Finn R.S.,Dering J., Conklin D., et al. PD0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptorpositive human breast cancer cell lines in vitro. Breast Cancer res. 2009;11(5):R77. doi: 10.1186/bcr2419
- Vidula N., Rugo H.S. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer. 2016;16(1):8-17. Doi: 10.1016/j. clbc.2015.07.005
- Giuliano M., Schettini F., RognoniC., et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2- negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet. Oncol. 2019;20(10):1360-69. doi: 10.1016/S1470- 2045(19)30420-6
- Gebbia V., Valerio M.R., Firenze A., et al. Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor. Expert Opin Drug Saf. 2020;19(8):945-54. doi: 10.1080/14740338.2020.1781814
- Lallena M.J., Boehnke K., Torres R., et al. Abstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines. Cancer Res. 2015;75(Suppl. 15):3101. doi: 10.1158/1538-7445.AM2015-3101
- Robert M., Frenel J.S., Bourbouloux E., et al. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer. Expert Opin Drug Metab Toxicol. 2019;15(2):85-91. doi: 10.1080/17425255.2019.1559816
- Goel S., DeCristo M.J., Watt A.C., et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471-75. Doi: 10.1038/ nature23465
- DeMichele A., Clark A.S., Tan K.S., et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015;21(5):995-1001. doi: 10.1158/1078- 0432.CCR-14-2258
- Infante J.R., Cassier P.A., Gerecitano J.F., et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016;22(23):5696-705. doi: 10.1158/1078-0432.CCR-16-1248
- Yamada Y., Ishikawa N., Kakizume T., et al. Abstract B31: a phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors. Mol Cancer Ther. 2015;14(12 suppl 2):B31. doi: 10.1111/cas.13428
- Dickler M.N., Tolaney S.M., Rugo H.S., et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218-24. doi: 10.1158/1078- 0432.CCR-17-0754
- Rugo H.S., Tolaney M., Cortes J., et al. Abstract CT044: MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. Cancer Res. 2017;77(Suppl.13) CT044. doi: 10.1158/1538-7445.AM2017- CT044
- Hamilton E., Cortes J., Ozyilkan O., et al. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clin Breast Cancer. 2020: doi: 10.1016/j. clbc.2020.09.011
- Palumbo A., Lau G., Saraceni M. Abemaciclib: The NewestCDK4/6InhibitorfortheTreatmentofBreast Cancer. Ann Pharmacother. 2019;53(2):178-85. doi: 10.1177/1060028018795146
- Gelbert L.M., Cai S., Lin X., et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/ independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825-37. doi: 10.1007/s10637- 014-0120-7
- Corona S.P., Generali D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018;12:321-30. doi: 10.2147/DDDT. S137783
- Sledge G.W. Jr, Toi M., Neven P., et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-84. doi: 10.1200/JCO.2017.73.7585
- Sledge G.W., Toi M., Neven P., et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019;6(1):116-24. doi: 10.1001/ jamaoncol.2019.4782
- Goetz M.P., Toi M., Campone M., et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638- 46. doi: 10.1200/JCO.2017.75.6155
- Johnston S., Martin M., Di Leo A., et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ. Breast Cancer. 2019;5:5. doi: 10.1038/s41523- 018-0097-z
- Di Leo A., Toi M., Campone M., et al. Ann. Oncol. 2017;28(Suppl. 5):v605-v649. Doi: 10.1093/ annonc/mdx440
- Sanchez-Martinez C., Gelbert L.M., Shannon H., et al. Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. Mol Cancer Ther. 2011;10(Suppl. 11):B234. doi: 10.1158/1535- 7163.TARG-11-B234
- Patnaik A., Rosen L.S., Tolaney S.M., et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6(7):740-53. doi: 10.1158/2159- 8290.CD-16-0095
- Tolaney S.M., Lin N.U., Thornton D., et al. Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. J Clin Oncol. 2017;35(Suppl. 15):1019. Doi: 10.1200/ JCO.2017.35.15_suppl.1019
- Kotake T., Toi M. Abemaciclib for the treatment of breast cancer. Expert Opin Pharmacother. 2018;19(5):517-24. doi: 10.1080/14656566.2018.1448787
- Tolaney S.M., Sahebjam S., Le Rhun E., et al. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020;26(20):5310-19. doi: 10.1158/1078- 0432.CCR-20-1764
- Howlett S., Harvey-Jones E., Smith D., et al. Does Concurrent Use of CDK4/6 Inhibitors During Palliative Radiotherapy Increase Toxicity in Patients With Metastatic Breast Cancer? Clin Oncol. (R Coll Radiol). 2021;33(1):e99. Doi: 10.1016/j. clon.2020.10.005
- Petrelli F., Ghidini A., Pedersini R., et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;174(3):597-604. doi: 10.1007/s10549-019-05133-y
- Messina C., Messina M., Zanardi E. Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer. Ann Oncol. 2017;28(12):3099- 100. doi: 10.1093/annonc/mdx530
- Ramos-Esquivel A., Hernández-Steller H., Savard M.F., et al. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. Breast Cancer. 2018;25(4):479-88. doi: 10.1007/s12282- 018-0848-6
- Ribnikar D., Volovat S.R., Cardoso F. Targeting CDK4/6 pathways and beyond in breast cancer. Breast. 2019;43:8-17. doi: 10.1016/j. breast.2018.10.001
- Scheicher R., Hoelbl-Kovacic A., Bellutti F., et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015;125(1):90-101. doi: 10.1182/blood2014-06-584417
- Desnoyers A., Nadler M.B., Kumar V., et al. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network metaanalysis. Cancer Treat Rev. 2020;90:102086. doi: 10.1016/j.ctrv.2020.102086
- Tamura K. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer. Jpn J Clin Oncol. 2019;49(11):993-98. doi: 10.1093/jjco/hyz151
- Sledge G.W. Abemaciclib Plus Fulvestrant Delays Breast Cancer Progression in MONARCH 2. ASCO Ann Meeting. 2017;Abstract 1000. Doi: 10.199/ Abst_199_180696
- Goetz M.P., Martin M., Tokunaga E., et al. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Оncol. 2020;25(9):e1346-54. Doi: 10.1634/ theoncologist.2020-0084
- Omori Y., Enatsu S., Cai Z., et al. Patients’ preferences forpostmenopausalhormone receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan. Breast Cancer. 2019;26(5):652-62. doi: 10.1007/s12282-019-00965-4
- Bossi P., Antonuzzo A., Cherny N.I., et al. ESMO Guidelines Committee. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv126-42. doi: 10.1093/annonc/mdy145
- Hurvitz S.A., Martin M., Press M.F., et al. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020;26(3):566-80. doi: 10.1158/1078-0432. CCR-19-1425
- Johnston S.R., Harbeck N., Hegg R., et al. monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987- 98. doi: 10.1200/JCO.20.02514
- Tolaney S.M., Wardley A.M., Zambelli S., et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standardof-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, openlabel, phase 2 trial. Lancet. Oncol. 2020;21(6): 763-75. doi: 10.1016/S1470-2045(20) 30112-1